Plasma cobalamin level as a considered tumor marker for hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancer among men and women. There are many serological tumor markers for the diagnosis of HCC. These are alpha-fetoprotein (AFP), des-gamma-carboxyprothrombin, vitamin B12 binding protein and HCC associated alkaline phosphatase. The aim of this study was to evaluate the possibility of using vitamin B12 as a tumor marker for HCC. This cross sectional study was performed during a 2 year period, and serum samples were obtained from 38 HCC, 57 noncancerous cirrhotic and 82 healthy control groups. Vitamin B12 levels were determined by using an automated chemiluminescence system test kit. All HCC patients also had an underlying cirrhotic pattern. The period of the previous liver disease was 30.7±26.3 month in cirrhotic patients and 15.4±10 month in the HCC group. AFP and vitamin B12 levels in HCC patients were significantly higher (median AFP: 219 ng/ml, median B12:1106 ng/ml) than cirrhosis patients (median AFP:9,7 ng/ml, median B12:445 ng/ml) and control group (median B12:442 ng/ml) (p<0,001). In the HCC group, there was a good positive correlation between level of vitamin B12 and AFP (p:0.002) but this correlation was not appeared in cirrhosis group. We also examined whether the correlation between the tumor size and vitamin B12 levels and AFP levels. There was no correlation between these parameters (p>0.05). Vitamin B12 levels can be useful as tumor marker in addition to other tumor markers and imaging modalities. Additional studies should be performed related to this subject and the other liver masses without malignancies.

___

1. Jennifer SA, Catherine TF. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver 2015; 9: 437-448.

2. Bruix J, Sherman M, Llovet JM, et al. Clinical management of Hepatocellular Carcinoma. J Hepatol 2001; 35: 421-430.

3. Vogel W, Klin W. Tumor markers in internal medicine. Hepatology 1989; 101: 484-489.

4. Kira S, Antony R, Amanda N, et al. Vitamin B12 and its binding proteins in hepatocellular carcinoma and chronic liver diseases. Scand J Gastroenterol 2014; 49: 1-7.

5. Katsuhiro I, Noritaka K, Soichiro A, et al. Hepatoprotective Effect of Vitamin B12 on Dimethylnitrosamine-Induced Liver Injury. Biol Pharm Bull 2008; 31: 309-311.

6. Fairbanks VF, Klee GG. Biochemical Aspects of Hematology. In: Burtis CA, Ashwood E R. Tietz textbook of Clinical Chemistry. Philadelphia: Saunders, 1999, pp 1690-1697.

7. Annette MS, Victor EV, Ray BN, Joseph AB. Immunohistochemical Quantification of the Vitamin B12 Transport Protein (TCII), Cell Surface Receptor (TCII-R) and Ki-67 in Human Tumor Xenografts. Anticancer Res 2013; 33: 4203-4212.

8. Anne LM, Anne-Mette H, Zoue¨ Lloyd-W, et al. Effect of Vitamin B12 Treatment on Haptocorrin. Clin Chem 2006; 52: 1104-1111.

9. Toshio K, Tsukasa T, Yukio K, Shigeru K, Naoto M. A Case of Postoperative Recurrence of Fibrolamellar Hepatocellular Carcinoma with Increased Vitamin B12 Binding Capacity in a Young Japanese Female. Jpn J Clin Oncol 2004; 34: 346-351.

10. Lildballe DL, Nguyen KQT, Poulsen SS, Nielsen HO, Nexoe E. Haptocorrin as marker of disease progression in fibrolamellar hepatocellular carcinoma. Eur J Surg Oncol 2011; 37: 72-79.

11. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1985; 56: 918-928.

12. Gaetano C, Bruno D, Giovanni Battista G, et al. Cancer of the liver Italian program investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-755.

13. Josep ML, Jordi B. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 840-845.

14. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging system in a cohort of 257 patients in Toronto. Gut 2002; 50: 881-885.

15. Lin CY, Kuo CS, Lu CL, Wu MY, Huang RF. Elevated serum vitamin B(12) levels in association with tumor markers as the prognostic factors predictive for poor survival in patients with hepatocellular carcinoma. Nutr Cancer 2010; 62: 190-197.

16. Goel A, Ramakrishna B, Muliyil J, et al. Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis. Dig Dis Sci 2013; 58: 179-187.

17. Hibertus H, Ion A, Chirstoph K, Armin S. Vitamin B12 and hepatic enzyme serum levels correlate in male alcohol dependent patients. Alcohol Alcohol 2001; 36: 26-28.

18. Nörredam K, Chaınuvatı T, Gımsıng P, Hıppe E. Plasma cobalamin and transcobalamin in patients with primary carcinoma of the liver. Scand J Gastroenterol 1983; 18: 229-232.

19. Kane SP, Murray-Lyon MI, Paradinas FJ, Johnson PJ, Williams R. Vitamin B12 binding protein as a tumour marker for hepatocellular carcinoma. Gut 1978; 19: 1105-1109.

20. Carmel R, Eisenberg L. Serum vitamin B12 and transcobalamins abnormalities in patients with cancer. Cancer 1977; 40: 1348-1353.

21. Boisson F, Fremont S, Migeon C, et al. Human haptocorrin in hepatocellular carcinoma. Cancer Detect Prev 1999; 23: 89-96.

22. Philip J, Johnson MD. The role of serum AlphaFetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145-159.